US 12,037,377 B2
LILRB1-based chimeric antigen receptor
Carl Alexander Kamb, Agoura Hills, CA (US); Agnes E. Hamburger, Agoura Hills, CA (US); Breanna Diandreth, Agoura Hills, CA (US); Mark E. Daris, Newbury Park, CA (US); and Kiran Deshmukh, Culver City, CA (US)
Assigned to A2 BIOTHERAPEUTICS, INC., Agoura Hills, CA (US)
Filed by A2 Biotherapeutics, Inc., Agoura Hills, CA (US)
Filed on May 12, 2022, as Appl. No. 17/663,148.
Application 17/663,148 is a continuation of application No. 17/589,088, filed on Jan. 31, 2022.
Application 17/589,088 is a continuation of application No. 17/230,637, filed on Apr. 14, 2021, granted, now 11,254,726, issued on Feb. 22, 2022.
Application 17/230,637 is a continuation of application No. PCT/US2020/064607, filed on Dec. 11, 2020.
Claims priority of provisional application 63/085,969, filed on Sep. 30, 2020.
Claims priority of provisional application 62/946,888, filed on Dec. 11, 2019.
Prior Publication US 2022/0289818 A1, Sep. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/705 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01)
CPC C07K 14/70503 (2013.01) [A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C07K 16/2833 (2013.01); C07K 16/3069 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/03 (2013.01)] 24 Claims
 
1. A T cell, comprising a chimeric antigen receptor, wherein the receptor comprises a polypeptide comprising:
a) an antigen binding domain comprising an scFv comprising the CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 of any one of SEQ ID NOs: 35-46;
b) a LILRB1 hinge domain;
c) a LILRB1 transmembrane domain; and
d) an LILRB1 intracellular domain comprising at least one immunoreceptor tyrosine-based inhibitory motif (ITIM) selected from the group consisting of NLYAAV (SEQ ID NO: 8), VTYAEV (SEQ ID NO: 9), VTYAQL (SEQ ID NO: 10), and SIYATL (SEQ ID NO: 11),
wherein the LILRB 1 hinge domain, transmembrane domain, and intracellular domain comprises a sequence at least 95% identical to SEQ ID NO: 2 or 3.